Findings

What do systematic reviews say?

28 questions · 28 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 10.7%GRADE not reported 0 · 0%Very low 6 · 21.4%Low 5 · 17.9%Moderate 13 · 46.4%High 1 · 3.6%

Oxcarbazepine vs control

Median percentage seizure reduction per 28 days · people with drug‐resistant focal epilepsy

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1494 participants
Moderate

Oxcarbazepine vs control

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Oxcarbazepine may leads to higher 50% or greater reduction in seizure frequency compared with control (low certainty).

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 1.8 [1.27, 2.56]
6 studies · 1593 participants
Low

Oxcarbazepine vs control

Ataxia · people with drug‐resistant focal epilepsy

Oxcarbazepine showed no clear difference in ataxia compared with control (moderate certainty).

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 2.54 [0.86, 7.54]
5 studies · 1227 participants
Moderate

Oxcarbazepine vs control

Hyponatraemia · people with drug‐resistant focal epilepsy

Oxcarbazepine showed no clear difference in hyponatraemia compared with control (moderate certainty).

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 2.53 [0.27, 23.85]
6 studies · 1593 participants
Moderate

Oxcarbazepine vs control

Somnolence · people with drug‐resistant focal epilepsy

Oxcarbazepine may leads to higher somnolence compared with control (low certainty).

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 2.03 [1.17, 3.54]
6 studies · 1593 participants
Low

Oxcarbazepine vs control

Seizure freedom · people with drug‐resistant focal epilepsy

Oxcarbazepine may leads to higher seizure freedom compared with control (low certainty).

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 2.86 [1.19, 6.87]
5 studies · 1494 participants
Low

Oxcarbazepine vs control

Treatment withdrawal · people with drug‐resistant focal epilepsy

Oxcarbazepine probably leads to higher treatment withdrawal compared with control (moderate certainty).

1 finding from 1 review

Oxcarbazepine add‐on for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 1.75 [1.44, 2.13]
6 studies · 1593 participants
Moderate

Oxcarbazepine vs placebo

At least 50% reduction in pain · painful diabetic neuropathy

It is very uncertain whether oxcarbazepine changes reduction in participant‐reported pain scores by at least 50% from… compared with placebo (very low certainty).

1 finding from 1 review

Oxcarbazepine for neuropathic pain 2017 · Cochrane Headline outcomes only
RR 1.91 [1.08, 3.39]
1 study · 146 participants
Very low

Oxcarbazepine vs placebo

At least 30% reduction in pain · painful diabetic neuropathy

It is very uncertain whether oxcarbazepine changes reduction in participant‐reported pain scores by at least 30% from… compared with placebo (very low certainty).

1 finding from 1 review

Oxcarbazepine for neuropathic pain 2017 · Cochrane Headline outcomes only
RR 1.57 [1.01, 2.44]
1 study · 146 participants
Very low

Oxcarbazepine vs placebo

Participants' global impression of their change in pain Participant's global assessment of therapeutic effect, 'much' or 'very much' · painful diabetic neuropathy

It is very uncertain whether oxcarbazepine changes participants' global impression of their change in pain… compared with placebo (very low certainty).

1 finding from 1 review

Oxcarbazepine for neuropathic pain 2017 · Cochrane Headline outcomes only
RR 1.46 [1.13, 1.88]
2 studies · 493 participants
Very low

Oxcarbazepine vs placebo

Serious adverse effects · painful diabetic neuropathy

Oxcarbazepine probably leads to higher serious adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Oxcarbazepine for neuropathic pain 2017 · Cochrane Headline outcomes only
RR 3.65 [1.45, 9.2]
3 studies · 634 participants
Moderate

Oxcarbazepine vs phenytoin

Time to treatment failure (any reason related to treatment) All participants Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin (primary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.78 [0.53, 1.14]
2 studies · 476 participants
Moderate

Oxcarbazepine vs phenytoin

Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 1.09 [0.75, 1.57]
2 studies · 326 participants
Moderate

Oxcarbazepine vs phenytoin

Time to 12‐month remission ‐ stratified by epilepsy type ‐ generalised onset Range of · people with newly diagnosed epilepsy

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.94 [0.55, 1.62]
2 studies · 142 participants
Low

Oxcarbazepine vs phenytoin

Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.69 [0.43, 1.09]
2 studies · 333 participants
Moderate

Oxcarbazepine vs phenytoin

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 1.03 [0.51, 2.08]
2 studies · 143 participants
Moderate

Oxcarbazepine vs phenytoin

Time to treatment failure due to adverse events All participants Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.22 [0.1, 0.51]
2 studies · 480 participants
High

Oxcarbazepine vs phenytoin

Time to treatment failure due to lack of efficacy All participants Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure due to lack of efficacy All participants… compared with phenytoin (primary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 1.17 [0.31, 4.35]
2 studies · 480 participants
Moderate

Oxcarbazepine vs phenytoin

Time to first seizure (post‐randomisation) All participants Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.97 [0.75, 1.26]
2 studies · 468 participants
Moderate

Oxcarbazepine vs phenytoin

Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy

Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin (secondary outcomes) (moderate certainty).

1 finding from 1 review

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.92 [0.68, 1.25]
2 studies · 326 participants
Moderate